This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.
View your own country’s website
Close

A dedicated women's health company

Close

Understanding contraceptive options to meet your needs

Close

Supporting you through the menopause

Close

Helping you thrive through osteoporosis

Close

Helping you through the challenges of fertility

Close

Theramex News

Close

Our diverse portfolio helps us deliver on our commitment to Women's Health

Close

Get in touch

Theramex news

Stay up to date with the latest news from Theramex.

Reset all filters

2 October 2023

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

Read more

14 August 2023

Theramex’s statement on the Women’s Health Strategy’s (WHS) one year anniversary

Read more

8 March 2023

Theramex enters into an exclusive licensing agreement with Radius Health Inc, to commercialise ELADYNOS®▼ in the European Economic Area, the United Kingdom, Australia and Brazil

Read more

17 June 2022

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the treatment of symptoms of Uterine Fibroids

Read more

14 April 2022

Theramex UK Stock Update

Read more

28 March 2022

A consortium of Carlyle and PAI Partners to acquire Theramex from CVC Funds

Read more

Load more

Read more about Theramex